Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vanda Pharma (VNDA) Buy Rating and $15 PT Reiterated - Jefferies
May 5, 2016 9:45 AM EDTJefferies analyst, Chris Howerton, maintained his Buy rating and $15 PT after Vanda (NASDAQ: VNDA) reported a strong 1Q with 3 takeaways:
1) Hetlioz - strong 1Q sales (~$16.2M vs Jef est. of ~$15.4M) suggt'ng ~80 net patient adds in our model; EU launch in 3Q16 mgmt... More
